期刊文献+

HPLC法测定利伐沙班中对映异构体的含量 被引量:6

Determination of Enantiomer in Rivaroxaban by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法测定利伐沙班中对映异构体含量。方法:色谱柱为 Chiralpak IA(250 mm ×4.6 mm,5μm),流动相为100%甲醇,流速为1.0 ml·min^-1,检测波长为250 nm,柱温为40℃。结果:利伐沙班与其对映异构体之间的分离度大于2.0,两者在0.5~1000.00μg·ml^-1范围内呈良好的线性关系,r均为0.9999,对映异构体检测限为0.17 ng,平均加样回收率为102.9%,RSD为1.54%(n=6)。结论:该方法准确、快速,可用于利伐沙班中对映异构体的含量测定。 Objective:To establish a method for the determination of enantiomer in rivaroxaban by HPLC. Methods:A Chiralpak IA column (250 mm × 4. 6 mm, 5 μm) was used with the mobile phase of 100% methanol. The flow rate was 1. 0 ml·min-1 . The detection wavelength was set at 250 nm and the column temperature was 40℃. Results:The resolution of rivaroxaban and the enanti-omer was above 2. 0. The linear range of them was 0. 5-1 000. 00 μg·ml^-1(r=0. 999 9). The detection limit of the enantiomer was 0. 17ng and the average recovery was 102. 9% with RSD of 1. 54%(n=6). Conclusion:The method is accurate and rapid, and suit-able for the determination of the enantiomer in rivaroxaban.
出处 《中国药师》 CAS 2014年第10期1629-1631,共3页 China Pharmacist
基金 科技部"十二五""重大新药创制"专项课题(编号:2013ZX09402103)
关键词 利伐沙班 对映异构体 高效液相色谱法 含量测定 Rivaroxaban Enantiomer HPLC Determination
  • 相关文献

参考文献4

  • 1Roehrig S, Staub A, Pohimann J, et al. Discovery of the novel an- tithrombotic agent 5-chloro-N-( { (5S) -2-oxo-3-[ 4- ( 3-oxomorpho- lin-4-yl) phenyl ] -1. 3-oxazolidin-5-yl } methyl ) thiophene-2-cabox- amide ( BAY59-7939 ) : an oral. Direct factor Xa inhibitor [ J ]. J Med Chem, 2005, 48(19) :5900-5908.
  • 2刘晓,崔一民.新型抗凝血药物——利伐沙班[J].中国药房,2010,21(1):83-86. 被引量:21
  • 3国家药典委员会编.中国药典[s].二部.北京:化学工业出版社.2010.附录14.472.
  • 4郭文敏,杨汉煜,白晓雪,邢浩,王丙林.HPLC法测定二甲氨基阿格拉宾盐酸盐的含量[J].中国药师,2013,16(10):1518-1520. 被引量:2

二级参考文献23

  • 1Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2- oxo-3-[4- (3-oxomorpholin-4-yl) phenyl]-1, 3-oxa- zolidin-5-yl}methyl) thiophene-2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[J]. Med Chem, 2005,48 ( 19 ) : 5 900.
  • 2Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban : An oral direct inhibitor of factor Xa[J].Am J Health Syst Pharm, 2008,65(16) : 1 520.
  • 3Perzbom E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct factor Xa inhibitor[J].J Thromb Haemost, 2005, 3(3) :514.
  • 4Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J].Clin Pharmacol Ther, 2005, 78(4) :412.
  • 5Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects[J].Eur J Clin Pharmacol, 2005, 61 (12):873.
  • 6Gerotziafas GT, Elalamy I, Depasse F, et al.In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban[J].J Thromb Haemost, 2007, 5(4) :886.
  • 7Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) : the ODIXa- DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study[J].Circulation, 2007,116( 2 ) : 180.
  • 8Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J].J Thromb Haemost, 2006, 4( 1 ) : 121.
  • 9Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59- 7939), for thromboprophylaxis after total hip replacement [J].Circulation, 2006, 114(22) : 2 374.
  • 10Turpie AG, Fisher WD, Bauer KA, et aI.BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II doseranging study[J].J Thromb Haemost, 2005, 3(11):2 479.

共引文献108

同被引文献48

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部